CC-292, A NOVEL BRUTON'S TYROSINE KINASE INHIBITOR ALONE AND IN COMBINATION WITH CARFILZOMIB IMPACTS BONE RESORPTION IN MULTIPLE MYELOMA BY BLOCKING OSTEOCLAST SEALING ZONE FORMATION

被引:0
|
作者
Eda, H. [1 ]
Loredana, S. [1 ]
Cirstea, D. [1 ]
Yee, A. [1 ]
Mahindra, A. [1 ]
Scullen, T. [1 ]
Nemani, N. [1 ]
Mishima, Y. [1 ]
Kapur, S. [2 ]
Evans, E. [3 ]
Singh, J. [3 ]
Kirke, C. [2 ]
Westlin, W. [3 ]
Raje, N. [1 ]
机构
[1] Harvard Med Sch, Canc Ctr, MGH, Boston, MA USA
[2] Onyx Pharmaceut Inc, Res Dept, San Francisco, CA USA
[3] Celgene Avil Res, Bedford, England
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
S543
引用
收藏
页码:227 / 228
页数:2
相关论文
共 21 条
  • [21] Development of a novel Bruton's tyrosine kinase inhibitor that exerts anti-cancer activities potentiates response of chemotherapeutic agents in multiple myeloma stem cell-like cells
    Elbezanti, Weam Othman
    Al-Odat, Omar S. S.
    Chitren, Robert
    Singh, Jaikee Kumar
    Srivastava, Sandeep Kumar
    Gowda, Krishne
    Amin, Shantu
    Robertson, Gavin P. P.
    Nemmara, Venkatesh V. V.
    Jonnalagadda, Subash C. C.
    Budak-Alpdogan, Tulin
    Pandey, Manoj K. K.
    FRONTIERS IN PHARMACOLOGY, 2022, 13